The degradation of platelet-activating factor in human serum depends primarily on PAF-acetylhydrolase bound to apoprotein B-containing lipoproteins (VLDL and LDL).
Answers are grounded in this paper and cite their sources.
Highlights lipoprotein-dominant PAF degradation in healthy serum; hypothesis-generating for atherothrombotic roles, no practice change indicated.
Platelet-activating factor (PAF) is rapidly degraded in vivo by the action of a specific acetylhydrolase. Measuring the PAF-acetylhydrolase activity in serum from 12 healthy volunteers a maximum velocity of 67.2 +/- 11.8 nmol/min X ml and a Km value of 15.8 +/- 2.9 mumol/l were ascertained. More than 90% of the activity was found to be associated with lipoproteins. It was detected in isolated VLDL, LDL, Lp(a) as well as HDL2 but not in HDL3. The PAF-acetylhydrolase activities associated with the various lipoproteins were shown to behave like a unique enzyme with distinct kinetic properties. Because VLDL and LDL were found to take up about 5 and 2.5 times more PAF with respect to their mass than HDL, it is concluded that lipoproteins affect the PAF-acetylhydrolase activity at the level of substrate presentation. As a consequence of the distinct kinetic properties, the lipoprotein-associated PAF-acetylhydrolase activities do not contribute proportionately to the degradation of PAF in serum. The latter is shown to depend primarily on the amount of PAF-acetylhydrolase bound to the apoprotein B-containing lipoproteins.
No takes yet. Share an insight, caveat, or question.
Ostermann et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: